Business Context and Reporting Period
This Form 8-K reports on the annual meeting of shareholders held by Oncocyte Corporation (trading symbol: OCX) on July 15, 2022. The meeting was conducted at the company's principal offices in Irvine, California, and via live webcast. Holders of 94,580,537 shares, representing 79.81% of the voting power as of the May 16, 2022 record date, participated in the meeting.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders voted on six proposals. The results were as follows:
- Election of Directors: All six nominees (Ronald Andrews, Jr., Andrew Arno, Jennifer Levin Carter, Melinda Griffith, Alfred D. Kingsley, and Andrew J. Last) were elected. Notably, Ronald Andrews, Jr. and Melinda Griffith received significant "withheld" votes (30.5M and 32.7M respectively) compared to other nominees.
- Ratification of Auditors: Shareholders ratified the appointment of WithumSmith+Brown, PC as the independent registered public accountants for the fiscal year ending December 31, 2022.
- Executive Compensation (Say-on-Pay): The advisory vote to approve named executive officer compensation for fiscal 2021 passed, though it was closely contested with 36.8M votes "For" and 34.8M votes "Against."
- Frequency of Say-on-Pay: Shareholders voted to hold the advisory vote on executive compensation annually (every 1 year).
- Equity Incentive Plan Amendment: Shareholders approved an amendment to the 2018 Equity Incentive Plan to eliminate "fungible share counting," ensuring shares granted count one-for-one against the available share pool.
- Preferred Stock Conversion and Warrant Exercise: Shareholders approved the issuance of common stock underlying securities issued to Broadwood in connection with a recent Preferred Stock Offer and Underwritten Offer, complying with Nasdaq Listing Rules regarding issuance of 20% or more of outstanding common stock.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risk factors. The primary operational implication noted is the approval of significant share issuance related to the Broadwood transaction, which impacts capital structure and dilution.
Key Facts for Investor Verification
- Verify the exact number of shares issued to Broadwood following the shareholder approval to assess dilution impact.
- Review the detailed proxy statement (filed June 8, 2022) for context on the significant "withheld" votes for directors Ronald Andrews, Jr. and Melinda Griffith.
- Monitor the company's capitalization table post-issuance to confirm compliance with Nasdaq listing rules regarding the 20% threshold.
- Check subsequent filings for the implementation of the "fungible share counting" amendment in future equity grants.